Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Cork M, Deleuran M, Geng B, Silverberg J, Simpson E, Stein Gold L, Johnson S, Romero W, Valdez H, Zhang M, Yin N October 2, 2021 EADV 2021 Atopic Dermatitis

Abrocitinib Treatment in Patients With Moderate-to-Severe Atopic Dermatitis: Safety of Abrocitinib Stratified by Age

View Presentation
Poster
Staumont-Sallé D, Barbarot S, Bouaziz J, Chan G, Clibborn C, Thanh A, Feeney C, Lejeune A, Misery L, Nosbaum A, Seneschal J, Soria A, Zhang F October 2, 2021 EADV 2021 Atopic Dermatitis

Effect of Abrocitinib and Dupilumab on Eosinophil Levels in the JADE COMPARE Phase 3 Clinical Trial

View Presentation
Oral Presentation
Reich K, Thyssen J, Blauvelt A, Eyerich K, Soong W, Rice Z, Hong H, Katoh N, Valenzuela F, DiBonaventura M, Bratt T, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkman U October 2, 2021 EADV 2021 Atopic Dermatitis

Efficacy and Safety of Abrocitinib Versus Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Who Received Background Topical Therapy in a 26-Week, Randomized, Head-to-Head Trial

View Presentation
Poster
Lynde C, Lin M, Hebert A, Russo C, Zang C, Graham D, Cha A October 2, 2021 EADV 2021 Atopic Dermatitis

Efficacy and Safety of Crisaborole in Asian Infants With Mild-to-Moderate Atopic Dermatitis in the CrisADe CARE 1 Study

View Presentation
Poster
Kataoka Y, Sinclair R, Matsumoto F, Nakamura K, Zhang F, Gamalo M, Rojo R, Romero W, Feeney C, Hirose R October 2, 2021 EADV 2021 Atopic Dermatitis

Efficacy Comparison of Abrocitinib and Dupilumab at the Individual Patient Level in the Phase 3 JADE COMPARE Study

View Presentation
Oral Presentation
Silverberg J, Simpson E, Thyssen J, Viguier M, Thaci D, Bruin-Weller M, Weidinger S, Chan G, DiBonaventura M, Biswas P, Feeney C, Koulias C October 2, 2021 EADV 2021 Atopic Dermatitis

Efficacy of Abrocitinib in Severe and Difficult-to-Treat Patients With Moderate-to-Severe Atopic Dermatitis in the Phase 3 JADE COMPARE Study

View Presentation
Poster
Alexis A, Silverberg J, Rice Z, Armstrong A, Desai S, Fonacier L, Kabashima K, Levenberg M, Biswas P, Rojo R, Chan G October 2, 2021 EADV 2021 Atopic Dermatitis

Efficacy of Abrocitinib Monotherapy for the Treatment of Moderate-to-Severe Atopic Dermatitis per Fitzpatrick Scale

View Presentation
Poster
Thyssen J, Silverberg J, Blauvelt A, Criado P, Gubelin W, Ruano J, Rojo R, Terry K, Valdez H, Biswas P, Feeney C October 2, 2021 EADV 2021 Atopic Dermatitis

Factors Associated with Persistent Efficacy of Abrocitinib Without Flare: A Multivariable Analysis of the JADE-REGIMEN Study

View Presentation
Poster
Thyssen J, Silverberg J, Yosipovitch G, Kwatra S, Carrascosa J, Brunner P, DiBonaventura M, Zhang F, Feeney C, Clibborn C, Rebollo F October 2, 2021 EADV 2021 Atopic Dermatitis

Impact of Comorbid Asthma on Patient-Reported Outcomes From Abrocitinib Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of the JADE COMPARE Phase 3 Study

View Presentation
Poster
Simpson E, Silverberg J, Zdybski J, Cork M, Paul C, Feeney C, Clibborn C, DiBonaventura M, Biswas P, Guler E October 2, 2021 EADV 2021 Atopic Dermatitis

Outcomes in Patients With Atopic Dermatitis and Asthma: Analysis From the JADE REGIMEN Trial

View Presentation